Pfizer Inc. ($PFE) has provided guidance for its full-year 2025 revenues, projecting a range of $61 billion to $64 billion, with adjusted diluted earnings per share expected between $2.80 and $3.00. The company's Chief Financial Officer indicated plans for biotech acquisitions in 2025, with a budget of $10 billion to $15 billion. Meanwhile, AstraZeneca ($AZN) reported an 18.1% increase in profits for 2024, totaling €6.796 billion. The company anticipates a high single-digit percentage increase in total revenue and a low double-digit percentage rise in core earnings per share for 2025. AstraZeneca's strong performance was attributed to significant sales growth in its cancer and immunology treatments, alongside a 38% increase in annual pretax profits. Philip Morris International ($PM) also reported a positive outlook, forecasting a strong start to 2025 with net revenue and operating income growth, and an expected adjusted IMS growth of around 10%.